Related Experiment Videos
Hypercoagulability: clinical assessment and treatment.
1Department of Education and Research, Baptist Regional Cancer Institute, Baptist Medical Center, Jacksonville, Fla 32207, USA.
Southern Medical Journal
|November 13, 2001
Summary
Hypercoagulability, a condition of increased clotting, involves various risk factors and can stem from inherited or acquired defects. Early assessment and tailored treatment are crucial for managing clotting risks.
Area of Science:
- Medical Science
- Hematology
- Pathophysiology
Background:
- Hypercoagulability increases the risk of thrombosis.
- Risk factors include obesity, surgery, pregnancy, and cancer.
- Coagulation abnormalities can be inherited or acquired.
Purpose of the Study:
- To review the pathophysiology, clinical features, assessment, and therapy for hypercoagulability.
- To highlight the complexities of diagnosing and managing clotting disorders.
- To provide guidance on when to consider hypercoagulability assessment.
Main Methods:
- Literature review focusing on hypercoagulability.
- Analysis of clinical features and diagnostic challenges.
- Synthesis of current therapeutic approaches and recommendations.
Main Results:
- Laboratory testing during acute thrombosis can be unreliable.
- Testing is most accurate when patients are not on anticoagulants.
- Multiple coagulation defects are frequently detected.
- Treatment typically involves heparin followed by warfarin, with variable duration.
Conclusions:
- Hypercoagulability assessment is recommended for patients with clotting and risk factors like malignancy or pregnancy.
- Asymptomatic individuals may not need treatment unless facing clot-promoting situations.
- Accurate diagnosis and individualized treatment plans are essential for managing hypercoagulability.